Repeat Dose Safety Study for Compound to Treat Hematologic Cancer

Status:
Completed

Trial end date:
2012-03-01

Target enrollment:

Participant gender:

The purpose of this study is to characterize the safety and tolerability of repeat doses of compound GSK2110183 in subjects with hematologic cancer.

Phase 1/Phase 2

Accenture